The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …

ciation (AHA) convened a writing committee. The ACCF and AHA adhere to a rigorous policy
regarding relationships with industry and other entities (RWI) of authors and peer reviewers …

Background In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute
coronary syndromes, ticagrelor reduced the composite outcome of cardiovascular death …

BACKGROUND: Vitamin K antagonists have been the standard oral antithrombotic used for
more than a half century for prevention and treatment of thromboembolism. Their limitations …

Coronary artery disease (CAD) is the leading cause of death and disability worldwide, and
its prevalence is expected to increase in the coming years. CAD events are caused by the …

Context Despite dual antiplatelet therapy, stent thrombosis remains a devastating and
unpredictable complication of percutaneous coronary intervention (PCI). Objective To …

Stroke remains a leading cause of death worldwide and the first cause of disability in the
western world. Ischemic stroke (IS) accounts for almost 80% of the total cases of strokes and …

Chronic kidney disease (CKD) is a pandemic public health problem, with 500 million people
worldwide estimated to have some form of kidney injury. 1 Survey data suggest that the …

Antithrombotic therapy represents the mainstay of treatment for prevention of recurrent
ischemic events in patients with atherothrombotic disease processes. Although the benefits …

Background In TAILOR‐PCI, genotype‐guided selection of P2Y12 inhibitors after
percutaneous coronary intervention did not significantly reduce the risk of ischemic events at …